We agree with the Administration’s recognition that the mental health crisis in America demands a new level of regulatory urgency and scientific ambition,” commented Incannex CEO Joel Latham. ”For ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, ...

Rachel Carr Shreves and Crystal Howard of Spencer Fane discuss the proposed federal rescheduling of cannabis to Schedule III ...

The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help ...

Youth cannabis use between ages 9 and 17 years is associated with slower cognitive development during a time of key brain ...

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in ...

A string of ASX-listed drug developers is due to release company-making – or breaking – pivotal clinical study results in ...

Carnival Cruise Line has updated its onboard prohibited items policy, with brand ambassador John Heald highlighting new ...

A UC San Diego study looked at marijuana use and cognitive development in more than 11,000 teenagers over the course of ...

A law that introduced new tax rates, age restrictions, penalties and licensure requirements for THC hemp-derived products in ...

A new UC San Diego study strengthens the growing body of evidence that marijuana use impacts adolescent brain development.